Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Immunomodulatory and anti-proliferative effects of canine adipose-derived stromal vascular fraction on peripheral blood mononuclear cells: An in vitro model for therapeutic applications.

Rana H., Choudhary RK.

Animal Study on Chronic Inflammation, Immune Modulation, published in Vet J (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Vet J (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41319893
DOI
10.1016/j.tvjl.2025.106520

Abstract (original English)

This study investigated the immunomodulatory and anti-proliferative effects of canine adipose-derived stromal vascular fraction (SVF) on peripheral blood mononuclear cells (PBMCs) from healthy and lymphoma-affected dogs. SVF, a rich source of mesenchymal stem cells (MSCs), was isolated from canine periovarian adipose tissue and characterized by flow cytometry (CD45, CD44, and CD90), immunocytochemistry, and gene expression analyses (CD44, CD90, and CD105). Coculturing SVF with PBMCs showed that SVF significantly increased the population doubling time and decreased Ki-67 expression in PBMCs (3.5-fold) in a dose-dependent manner. Furthermore, SVF exhibited immunomodulatory properties by remarkably down-regulating the pro-inflammatory cytokine TNF-α (44-fold; p = 0.0003) and up-regulating the anti-inflammatory cytokine PTGS1 (88-fold; p = 0.008). These findings confirm that canine SVF contains functional MSCs and possesses significant immunomodulatory and anti-proliferative capabilities against PBMCs, suggesting its therapeutic potential. This study also demonstrates coculture of SVF and PBMC as an in vitro model for studying therapeutic applications of stem cells in canine inflammatory and proliferative conditions.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsDogsLeukocytes, MononuclearAdipose TissueCell ProliferationMesenchymal Stem CellsFemaleStromal Vascular FractionCoculture TechniquesDog Diseases

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research